Physician profile
Sahil Kumar Sharma
NPI 1164167581
$3,100.91
in general payments reported to CMS, 2019-2025
40 companies · $509 in 2025
The $509 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $599 · 2023: $1,450 · 2024: $542 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $400.71 | 2022-2024 | Imbruvica, Darzalex, Talvey |
| Lilly USA, LLC | $365.32 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $298.22 | 2023-2025 | Evenity, Prolia, Otezla |
| Exact Sciences Corporation | $171.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $161.29 | 2022-2023 | Opdualag |
| Novartis Pharmaceuticals Corporation | $154.32 | 2022-2024 | |
| Octapharma USA, INC. | $129.99 | 2023 | Panzyga, Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $103.61 | 2022-2023 | |
| Incyte Corporation | $97.22 | 2022-2023 | Jakafi, Pemazyre, Monjuvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.18 | 2025 | Caplyta |
| Seagen INC. | $78.40 | 2022-2023 | Adcetris |
| Abbvie INC. | $78.33 | 2022-2025 | |
| Eisai INC. | $72.05 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.36 | 2022-2023 | Alunbrig |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.56 | 2022-2023 | Xifaxan |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.